Detalhe da pesquisa
1.
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN).
Euro Surveill
; 29(7)2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38362622
2.
Risk of hospital admission and death from first-ever SARS-CoV-2 infection by age group during the Delta and Omicron periods in British Columbia, Canada.
CMAJ
; 195(42): E1427-E1439, 2023 10 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37903524
3.
Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23.
Euro Surveill
; 28(5)2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729117
4.
Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada.
CMAJ
; 194(47): E1599-E1609, 2022 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507788
5.
Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada.
Euro Surveill
; 27(38)2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36148674
6.
Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 2020, British Columbia, Canada.
Front Immunol
; 13: 836449, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35401521